Epigenetic Mechanisms of Cancer and Cell Differentiation
- Altres grups
- Regulatory Genomics
- Chromatin and Cell Fate
- Disease Genomics
- Epigenetic Mechanisms of Cancer and Cell Differentiation
- Cancer Genetics and Epigenetics
- Cancer and Iron
- ICO-IDIBELL-IGTP* Joint Program - Genetic Diagnostics
- Genetic Variation and Cancer
- Genomics and Bioinformatics
- ABO Histo-Blood Groups and Cancer
- Cancer Genome Biology
The Epigenetic Mechanisms of Cancer and Cell Differentiations Group now forms part of the Program for Predictive and Personalized Medicine of Cancer at the Germans Trias i Pujol Research Institute (IGPT) on the Can Ruti Campus. Please see the IGTP website here.
This page is currently being kept up to date, for information about the institute please see the IGTP page.
The main focus of our research is the characterization of the molecular mechanisms underlying cancer cell programs and the identification of molecular markers with clinical applications. The specific topics we are currently developing in our lab include:
- Chromatin architecture in cell differentiation and cancer. We are investigating the organization of chromatin in normal and cancer cells. We are especially interested in the characterization of the mechanisms determining long range interactions and genome compartmentalization.
- The role of repeat elements in genome structure and function. About half of the human genome is composed by repeat sequences. We are analyzing the epigenetics of some of these elements in normal and cancer cells and trying to determine their contribution to regulate the structure of the chromatin and gene expression.
- Clinically oriented research on the epigenetic changes involved in human cancer. Initiation and progression of cancer disease is accompanied by multiple molecular changes, including epigenetic alterations. We search for epigenetic markers appearing early in the disease to facilitate cancer detection and intervention. Our group also devotes a large effort to develop or adapt molecular techniques to clinical settings with the aim of translating science progress in a better management of patients. Most of our studies are focused on colorectal cancer.
- Epigenetic mechanisms during muscle lineage-commitment, cell activation and terminal differentiation. Muscle development and regeneration is driven by myogenic factors and epigenetic changes. We investigate the mechanisms and crosstalk of the different elements involved in these processes in physiological and pathological models.
Moreover, our lab aims to contribute to the advance of Genomic Medicine by developing new technologies and bioinformatic tools (more info at http://maplab.cat). Our group has also created Aniling (http://aniling.com), a spin-off of the IGTP focused on the improvement of next generation genomic technologies to integrate molecular data into biologically and clinically meaningful information.
Functional anatomy of cancer epigenomic architecture / SAF 2015-64521-R
Investigador principal Finançadors Data d'inici Data de finalització Miguel A. Peinado MINECO 01-01-2016 31-12-2018
GEUS: Unified analysis of genome and epigenome with high fidelity / M.A. Peinado/L. Coll/ V. Moreno / RTC-2015-3867-1
Investigador principal Finançadors Data d'inici Data de finalització Miguel A. Peinado MINECO 01-01-2015 31-12-2018
A new mechanism of action of Azacitidine beyond DNA hypomethylation in human cancer. A pilot study. GRANT-ESP-063
Investigador principal Finançadors Data d'inici Data de finalització Miguel A. Peinado Celgene SL 01-01-2017 31-12-2018
Deciphering the contribution of epigenetic modifiers in muscle cell identity, differentiation and growth / BFU2016-80748-P
Investigador principal Finançadors Data d'inici Data de finalització Mònica Suelves MINECO 01-01-2017 31-12-2019
Office 2-2, Lab 2-1 (second floor)
(+34) 93 554 3050
Mallona I, Díez-Villanueva A, Martín B, Peinado MA. Chainy, an universal tool for standardized relative quantification in real-time PCR. Bioinformatics 2017 Jan;
Jorda M, Díez-Villanueva A, Mallona I, Martín B, Lois S, Barrera V, Esteller M, Vavouri T, Peinado MA. The epigenetic landscape of Alu repeats delineates the structural and functional genomic architecture of colon cancer cells. Genome Res. 2017 Jan; 27(1): 118-132
Suelves M, Carrió E, Núñez-Álvarez Y, Peinado MA. DNA methylation dynamics in cellular commitment and differentiation. Brief Funct Genomics 2016 Nov; 15(6): 443-453
Carrió E, Magli A, Muñoz M, Peinado MA, Perlingeiro R, Suelves M. Muscle cell identity requires Pax7-mediated lineage-specific DNA demethylation. BMC Biol. 2016 Apr; 14: 30
Buj R, Mallona I, Díez-Villanueva A, Barrera V, Mauricio D, Puig-Domingo M, Reverter JL, Matias-Guiu X, Azuara D, Ramírez JL, Alonso S, Rosell R, Capellà G, Perucho M, Robledo M, Peinado MA, Jorda M. Quantification of unmethylated Alu (QUAlu): a tool to assess global hypomethylation in routine clinical samples. Oncotarget 2016 Mar; 7(9): 10536-46
Cebola I, Custodio J, Muñoz M, Díez-Villanueva A, Paré L, Prieto P, Aussó S, Coll-Mulet L, Boscá L, Moreno V, Peinado MA. Epigenetics override pro-inflammatory PTGS transcriptomic signature towards selective hyperactivation of PGE2 in colorectal cancer. Clin Epigenetics 2015; 7: 74
Díez-Villanueva A, Mallona I, Peinado MA. Wanderer, an interactive viewer to explore DNA methylation and gene expression data in human cancer. Epigenetics Chromatin 2015; 8: 22
Carrió E, Díez-Villanueva A, Lois S, Mallona I, Cases I, Forn M, Peinado MA, Suelves M. Deconstruction of DNA methylation patterns during myogenesis reveals specific epigenetic events in the establishment of the skeletal muscle lineage. Stem Cells 2015 Jun; 33(6): 2025-36
Barrera V, Peinado MA. Evaluation of single CpG sites as proxies of CpG island methylation states at the genome scale. Nucleic Acids Res. 2012 Dec; 40(22): 11490-8
Cebola I, Peinado MA. Epigenetic deregulation of the COX pathway in cancer. Prog. Lipid Res. 2012 Oct; 51(4): 301-13
Mayor R, Casadomé L, Azuara D, Moreno V, Clark SJ, Capellà G, Peinado MA. Long-range epigenetic silencing at 2q14.2 affects most human colorectal cancers and may have application as a non-invasive biomarker of disease. Br. J. Cancer 2009 May; 100(10): 1534-9